Publications by authors named "Niuscha Yaktapour"
Patients with BRAFV600E/K-driven melanoma respond to the BRAF inhibitor vemurafenib due to subsequent deactivation of the proliferative RAS/RAF/MEK/ERK pathway. In BRAF WT cells and those with mutations that activate or result in high levels of the BRAF activator RAS, BRAF inhibition can lead to ERK activation, resulting in tumorigenic transformation. We describe a patient with malignant melanoma who developed chronic lymphocytic leukemia (CLL) in the absence of RAS mutations during vemurafenib treatment.
View Article and Find Full Text PDFArticle Synopsis
- * Knocking down IGF1R in CLL cells reduces their survival, while its inhibition leads to cell death, even in supportive environments.
- * Sorafenib, a multikinase inhibitor, targets IGF1R and reduces its activity, showing promise as a therapeutic option for CLL treatment.